For life sciences founders, going public may be about to get a lot easier
By David Lange, Partner, Governance, Risk and Compliance, Weaver For twenty years, the rising cost of being a public company has pushed many startups to stay private as long as they could. A proposal out of Washington and a shift underway in Texas could rewrite that math. Many life sciences companies that succeed will face a decision about whether or not to go public. In theory it should be an easy call, since the public...











